$SLP News

Last published 1mo ago

1mo agoSLPSimulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with TurinBusiness WireCollaboration will apply Turin to explore mechanistic QSP model structures at scale and bring insights to development decisions where traditional modeling timelines have limited their use Simulations Plus, Inc.
1mo agoSLPSimulations Plus Announces Completion of Acquisition by AltarisBusiness WireSimulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the
1mo agoSLPSimulations Plus Expands FDA Adoption of ADMET Predictor® with New Licenses for the Cosmetics Regulatory Science BranchBusiness WireAgency will use the software platform to support modern cosmetic safety assessment through integrated exposure and toxicity modeling. Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the
3mo agoSLPSimulations Plus Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by AltarisBusiness WireSimulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, announced the
3mo agoSLPSimulation Plus, Inc. (NASDAQ: SLP) Investors Should Contact Robbins LLP for Information About InvestigationBusiness WireRobbins LLP announces that it is investigating Simulation Plus, Inc. (NASDAQ:SLP) to determine whether certain officers and directors violated securities laws or breached fiduciary duties owed to shareholdersThe
4mo agoSLPSimulations Plus Reports Third Quarter Fiscal 2026 Financial ResultsBusiness WireSimulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported
4mo agoSLPSimulations Plus Advances Agentic Drug Development with NVIDIA BioNeMo Agent ToolkitBusiness WireNew capabilities connect AI agents, scientific literature, and validated computational engines to accelerate model-informed drug development Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the
4mo agoSLPSimulations Plus to Be Acquired by Altaris For Approximately $375 MillionBusiness WireStockholders to Receive $18.50 Per Share in Cash Representing a 26% Premium to 60-day Volume-Weighted Average Price Transaction to Strengthen Simulations Plus and Accelerate Growth Through Anticipated Combination with
5mo agoSLPRobbins LLP Reminds SLP Stockholders of its Investigation into Simulation Plus, Inc.; Contact the Firm for InformationGlobeNewswireSAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Simulation Plus, Inc. (NASDAQ:SLP) to determine whether certain Simulation Plus officers and directors violated
5mo agoSLPRobbins LLP is Investigating Allegations that the Officers and Directors of Simulations Plus, Inc. (SLP) Violated Securities Laws and Breached Fiduciary Duties to ShareholdersBusiness WireShareholder rights law firm Robbins LLP is investigating Simulation Plus, Inc. (NASDAQ:SLP) to determine whether certain Simulation Plus officers and directors violated securities laws and breached fiduciary duties to
5mo agoSLPSimulations Plus to Participate in the 23rd Annual Craig-Hallum Institutional Investor ConferenceBusiness WireSimulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that Shawn O'Connor,
6mo agoSLPSimulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling WorkflowsBusiness WireCombines validated scientific engines with accelerated computing and AI to enable more scalable, integrated modeling workflows across the drug development lifecycle Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations
6mo agoSLPSimulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug ProductsBusiness WireMechanistic modeling approach and experimental integration designed to improve early risk identification, strengthen regulatory confidence, and expand AI-enabled workflows connecting data to
6mo agoSLPSimulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring SchoolBusiness WireMore than 1,400 participants across 65+ countries underscores accelerating adoption of model-informed workflows and growing demand for applied modeling expertise Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"
7mo agoSLPSimulations Plus Reports Second Quarter Fiscal 2026 Financial ResultsBusiness WireRevenue grew 8% with increases in both software and services Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that
7mo agoSLPSimulations Plus Announces Second Quarter Fiscal Year 2026 Earnings and Conference Call DateBusiness WireConference call to be on Thursday, April 9, 2026, at 5 p.m. ET Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus", "SLP"), a global leader in model-informed and AI-accelerated drug development that advances
7mo agoSLPSimulations Plus Announces Strategic Collaboration Programs for AI-Enabled ModelingBusiness WireCo-development initiatives to advance next-generation workflows, accelerate adoption, and expand the role of AI within model-informed drug development Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the
8mo agoSLPSimulations Plus Convenes Industry and Regulatory Leaders to Define Responsible AI in MIDDBusiness WireExpert panel at the 2026 ASCPT Annual Meeting brings together leaders with industry and regulatory experience to explore practical, accountable AI implementation Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"
9mo agoSLPSimulations Plus Announces Extensions of U.S. FDA and NIEHS Research CollaborationsBusiness WireExtended projects support ongoing research into computational approaches and new approach methodologies for food and chemical safety assessment Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the
9mo agoSLPSimulations Plus to Participate in Upcoming Investor ConferencesBusiness WireSimulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus", "SLP"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that Shawn O'Connor, Chief
10mo agoSLPSimulations Plus Reports First Quarter Fiscal 2026 Financial ResultsBusiness WireInvestor Day on January 21, 2026, to present new product vision and AI solutions Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug
10mo agoSLPSimulations Plus to Host Virtual Investor Day Highlighting Strategy for the Next Era of Model-Informed Drug DevelopmentBusiness WireDriving Growth with Integrated Software, Services, and AI-Enabled Ecosystem Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug
10mo agoSLPSimulations Plus Announces First Quarter Fiscal Year 2026 Earnings and Conference Call DateBusiness WireConference call to be on Thursday, January 8, 2026, at 5 p.m. ET Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus", "SLP"), a global leader in model-informed and AI-accelerated drug development that advances
11mo agoSLPSimulations Plus Positioned to Capitalize on FDA's Streamlined Nonclinical Safety Guidance with Advanced Mechanistic and Model-Informed SolutionsBusiness WireValidated engines and AI-orchestrated ecosystem align with the emerging regulatory framework Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and
11mo agoSLPSimulations Plus Reports Fourth Quarter and Fiscal 2025 Financial ResultsBusiness WireReaffirms fiscal 2026 revenue guidance of $79 to $82 million and adjusted diluted EPS guidance of $1.03 to $1.10 Investor Day on January 21, 2026, to present new product vision and AI solutions Simulations Plus,
1y agoSLPSimulations Plus Announces Preliminary Fiscal Year 2025 Results and Fiscal Year 2026 GuidanceBusiness WireProvides preliminary fiscal 2026 revenue guidance of $79 to $82 million and adjusted diluted EPS guidance of $1.03 to $1.10 Fourth quarter and fiscal year 2025 results to be reported December 1, 2025 Simulations
1y agoSLPSimulations Plus, Inc. (SLP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Earnings Call Transcripts
1y agoSLPSimulations Plus to Participate in Upcoming Investor ConferencesBusiness WireSimulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus", "SLP"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the
1y agoSLPSimulations Plus and the Institute of Medical Biology of the Polish Academy of Sciences Partnership Announces Results in Validation of ADMET Predictor® Models with Enhanced AI Drug DesignBusiness WireResearchers found 70% of compounds designed in ADMET Predictor demonstrated significant activity during in vitro testing Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of cheminformatics,
1y agoSLPSimulations Plus Invests in Clinical Development Technology Company NurocorBusiness WireInvestment to accelerate innovations in biopharma development through Corporate Development Initiative Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation,
1y agoSLPSimulations Plus Reports Third Quarter Fiscal 2025 Financial ResultsBusiness WireUpdated full-year revenue guidance of between $76 to $80 million and adjusted diluted EPS of $0.93 to $1.06 Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a leading provider of
1y agoSLPSimulations Plus Announces Rescheduling of Third Quarter Fiscal 2025 Earnings Release and Conference CallBusiness WireTo be released on July 14, 2025, with conference call at 5 p.m. ET Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a leading provider of cheminformatics, biosimulation, simulation-enabled
1y agoSLPSimulations Plus to Participate in the Citizens Medical Devices and Healthcare Services ForumBusiness WireSimulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus", "SLP"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the
1y agoSLPSimulations Plus Announces Preliminary Third Quarter Fiscal 2025 RevenueBusiness WireUpdates fiscal 2025 revenue guidance range Third quarter fiscal 2025 full results to be released on July 2, 2025, with conference call at 5 p.m. ET Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the
1y agoSLPSimulations Plus Releases ADMET Predictor® 13Business WireExpanded functionality and advanced AI/ML capabilities deliver faster, more accurate predictions and streamline enterprise deployment Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of
1y agoSLPSimulations Plus Releases DILIsym® 11Business WireNewest version of the quantitative systems toxicology (QST) software supports drug-induced liver injury (DILI) prediction for pediatric patient populations Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a
1y agoSLPSimulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety StudiesBusiness WireModeling and simulation will be a key component for shift to non-animal methodologies Introducing NAMVantage(TM), a flagship package offering PBPK and QSP professional services and regulatory strategy combined with
1y agoSLPSimulations Plus Reports Second Quarter Fiscal 2025 Financial ResultsBusiness WireTotal revenue grew 23% year-over-year driven by strong growth in both software and services Maintains full-year revenue guidance of $90 to $93 million and adjusted diluted EPS of $1.07 to $1.20 Simulations Plus, Inc.
1y agoSLPSimulations Plus Announces Second Quarter Fiscal Year 2025 Earnings and Conference Call DateBusiness WireConference call to be on Thursday, April 3, 2025, at 5 p.m. ET Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus", "SLP"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and
1y agoSLPSimulations Plus to Present at the KeyBanc Capital Markets Virtual Healthcare Investor ForumBusiness WireSimulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus", "SLP"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the
1y agoSLPSimulations Plus to Participate in Upcoming Healthcare Investor ConferencesBusiness WireSimulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus", "SLP"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the
1y agoSLPSimulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® EnhancementsBusiness WireIndustry partners to provide funding and data to support ACAT™ model improvements Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance
1y agoSLPSimulations Plus Supported Development of Every FDA-Approved Drug in 2024Business WireSLP's technology and expertise accelerates drug development and supports critical advancements in global healthcare Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of cheminformatics,
1y agoSLPSimulations Plus Reports First Quarter Fiscal 2025 Financial ResultsBusiness WireTotal revenue up 31% year-over-year primarily driven by strong software growth Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled
1y agoSLPSimulations Plus Announces First Quarter Fiscal Year 2025 Earnings and Conference Call DateBusiness WireConference call to be on Tuesday, January 7, 2025, at 5 p.m. ET Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions,
1y agoSLPSimulations Plus to Participate in the BTIG Digital Health ForumBusiness WireSimulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today
1y agoSLPSimulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting InjectablesBusiness WireFunded collaboration will leverage current FDA partnership to include additional LAI technologies Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled
2y agoSLPSimulations Plus to Participate in the Stephens Annual Investment ConferenceBusiness WireSimulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today
2y agoSLPSimulations Plus and Partners Awarded New FDA Grant to Validate In Vitro-In Vivo Extrapolation Methods for Complex FormulationsBusiness WireCollaboration goal to develop alternative methods to assess clinical performance of product variants under different conditions Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of
2y agoSLPSimulations Plus, Inc. (SLP) Q4 2024 Earnings Call TranscriptEarnings Call Transcripts